Key Takeaways on the Treatment of Patients With Relapsed/Refractory MM
The expert panel closes the discussion with key takeaways on the relapsed/refractory multiple myeloma treatment landscape.
Treatment Decision-Making in Multiple Myeloma
Multiple myeloma–treating oncologists provide comprehensive insights on deciding between bispecific antibody monotherapy, combination therapy, and CAR T-cell therapy.
Toxicities From GPRC5D-Targeting Therapies in Multiple Myeloma
The panel continues their discussion on adverse effect management with a focus on GPRC5D-targeting bispecific antibodies in multiple myeloma.
MM: Managing Toxicities From BCMA-Targeting Bispecific Antibodies
Multiple myeloma specialists discuss the management of toxicities from BCMA-targeting bispecific antibodies.
Managing Adverse Effects from Bispecific Antibodies in Multiple Myeloma
Comprehensive insights on the management of adverse effects from bispecific antibodies in the treatment of multiple myeloma.
Dosing Considerations for Bispecific Antibodies in MM
Expert oncologists discuss dosing considerations for bispecific antibodies in the treatment of patients with multiple myeloma.
Recent Data on Bispecific Antibodies in Multiple Myeloma
A review of clinical trial data on bispecific antibodies in multiple myeloma and clinical insights on how these medications have changed clinical practice.
Multiple Myeloma Treatment: Patient Profiles
The panel reviews the profiles of 2 patients with multiple myeloma and provides their initial thoughts regarding treatment approaches.
Treatment Decision-Making in Early-Relapse MM
Expert perspectives on treatment decision-making in early-relapse multiple myeloma and the efficacy of CAR T-cell therapy.
Recent Data in the Management of Early-Relapse Multiple Myeloma
A panel of oncologists give an overview of clinical trial data surrounding the management of early-relapse multiple myeloma.